 |
Indication & Dosage |
| |
| |
| Oral |
| UNCOMPLICATED PREMATURE LABOUR |
| Adult:
Start oral therapy 30-60 mins before termination of IV infusion at 10 mg every 2 hr for 24 hr. Subsequently, 10-20 mg every 4-6 hr according to patient's response. Max oral dose 120 mg daily. |
| |
| Parenteral |
| UNCOMPLICATED PREMATURE LABOUR |
| Adult:
Given as IV infusion, initially 0.05 mg/min. Increase by 0.05 mg/min every 10 min until patient responds. Usual rate: 0.15-0.35 mg/min. As IM inj: 10 mg every 3-8 hr. Maintain for 12-48 hr after the contractions have stopped |
|
| |
|
| Precautions |
CV risk factors, concurrent steroids, hyperthyroidism, myocardial insufficiency, arrhythmias, hypertension, DM, bronchial asthma treated with beta-agonists, lactation. Monitor plasma glucose and potassium. Monitor maternal pulse throughout infusion; adjust rate to avoid maternal heart beat exceeding 140 beats/min. Monitor patient's hydration status to reduce risk of pulmonary oedema. Discontinue treatment if there are signs of pulmonary oedema. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Tachycardia, palpitation, headache, nervousness, anxiety, nausea, vomiting. |
| |
|
| Adverse Drug Reactions |
Rarely, anaphylaxis, arrhythmia, pulmonary oedema, hypokalaemia. |
| |
|
| Interactions |
Potassium-depleting drugs may increase risk of hypokalaemia. May enhance neuromuscular blockade produced by pancuronium and vecuronium. |
| |
|
|
|
